Derivative exercise or conversion — not an open-market buy.
Loading…
Traded Oct 7, 2025 · Filed Oct 9, 2025
The boss of ResMed| sold $2.27M of ResMed| shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$2,265,332
Shares × reported transaction price
68 days after results of Jul 31, 2025, 23 days before results of Oct 30, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $283.28 on Oct 7, 2025, within 4% of its 52-week high, little changed over the previous 30 trading days
52-week range $204.54 (Apr 8, 2025) to $293.73 (Aug 22, 2025), 88% of the way up, from 250 adjusted closes. 30 trading days earlier: $285.80 on Aug 25, 2025. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -1.4% | +1.7% | -3.2% |
| 30 days | -8.1% | +4.3% | -12.4% |
| 90 days | -7.8% | +5.6% | -13.3% |
| 180 days | -15.2% | +3.5% | -18.7% |
Past results only. Not a forecast.
Derivative exercise or conversion — not an open-market buy.
Derivative exercise or conversion — not an open-market buy.